--- title: "Primara Labs Changelog: What Changed and When" url: https://www.primaralabs.com/changelog source: Primara Labs, markdown mirror of the HTML page --- # What changed, and when. The most recent change to primaralabs.com was on 23 September 2026. Each entry below is dated and links to what changed, so a reader can see how current any page is. Updated 23 September 2026 8 entries ## Newest first 1. 23 September 2026 ### Answers to the questions buyers ask 48 answer pages, each opening with a dated direct answer and citing the source of every figure: approval status by compound, trial results and side effects, what lab tests show and cost, ordering, price and delivery. 5 Taglish versions await review before they are indexed. - [Answers](https://www.primaralabs.com/answers) 2. 23 September 2026 ### Supplier checklist and delivery checker Two new tools: 10 checks to apply to any peptide seller in the Philippines, with how Primara answers each, and a checker that gives the delivery window, courier, fee and cutoff for any covered city or province. - [Supplier checklist](https://www.primaralabs.com/tools/supplier-checklist) - [Delivery checker](https://www.primaralabs.com/tools/delivery-checker) 3. 23 September 2026 ### Fact sheet, press kit and entity data The facts about Primara Labs in one place, each generated from the file that holds it, with a press kit and the same facts as JSON. Every structured-data reference to the business now points at one organization record. - [Fact sheet](https://www.primaralabs.com/facts) - [Press](https://www.primaralabs.com/press) 4. 23 September 2026 ### Machine-readable pages Every public page is also available as markdown at its path plus .md, the full text of product, research and answer pages is in one file at /llms-full.txt, and the sitemap is split by section with real last-changed dates. - [llms-full.txt](https://www.primaralabs.com/llms-full.txt) 5. 23 September 2026 ### Identity and status corrections Molecular formulas in the catalogue checked against PubChem and corrected or withheld; the TB-500 and CJC-1295 specifications read "Confirming with supplier" until the supplier confirms the molecule. The tirzepatide and semaglutide descriptions now separate the US-approved medicines from the research vial. The FDA Philippines advisories list grew to 8. - [Regulatory Status Tracker](https://www.primaralabs.com/research/status) - [Catalogue](https://www.primaralabs.com/marketplace) 6. 23 September 2026 ### The Research Desk 9 free datasets and two tools on the compounds in the catalogue: an Evidence Map, a Trial Explorer, a Regulatory Status Tracker, a COA Reader and a Lab Test Planner, every figure linked to its primary source and dated, each dataset downloadable as JSON and CSV. - [Research Desk](https://www.primaralabs.com/research) - [Data](https://www.primaralabs.com/data) 7. 23 September 2026 ### Product pages rebuilt All 17 product pages now carry the benefits studied with their evidence level, the side effects reported, how the compound works, what the research shows, a specification sourced to PubChem, handling, batch reports and regulatory status. - [Catalogue](https://www.primaralabs.com/marketplace) 8. 23 September 2026 ### First batch report published Retatrutide batch RETA-4728-A is Janoshik-tested for bacterial endotoxin: 6.066 EU per vial, analysed 21 September 2026 (task 234146, key H2KI86I8GWB4). This report covers bacterial endotoxin only. It does not establish identity or purity. - [Batch reports](https://www.primaralabs.com/coa) - [Batch RETA-4728-A](https://www.primaralabs.com/batch/reta-4728-a)